We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $542M
1-Year Est. Return 206.64%
This Fund
S&P 500
This Quarter Est. Return
+28.45%
1 Year Est. Return
+206.64%
3 Year Est. Return
+724.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$542M
AUM Growth
+$42.4M
Cap. Flow
+$30.9M
Cap. Flow %
5.7%
Top 10 Hldgs %
64.55%
Holding
57
New
7
Increased
11
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
BTSG icon
BrightSpring Health Services
BTSG
+$25.7M
2
ALKS icon
Alkermes
ALKS
+$17.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$11.9M
4
RVMD icon
Revolution Medicines
RVMD
+$8.82M
5
CELC icon
Celcuity
CELC
+$5.05M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$35.2M
2
ABVX
Abivax
ABVX
+$9.54M
3
TERN
Terns Pharmaceuticals
TERN
+$5.53M
4
INSM icon
Insmed
INSM
+$4.8M
5
ABBV icon
AbbVie
ABBV
+$3.15M

Sector Composition

Rank Sector Weight
1 Healthcare 97.08%
2 Miscellaneous 2.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SION
26
Sionna Therapeutics
SION
$330M
$5.27M 0.97%
119,741
– –
ASND icon
27
Ascendis Pharma A/S
ASND
$17.7B
$4.73M 0.87%
17,740
– –
ROIV icon
28
Roivant Sciences
ROIV
$30B
$4.59M 0.85%
129,800
– –
PALI icon
29
Palisade Bio
PALI
$383M
$4.16M 0.77%
1,992,367
– –
EWTX icon
30
Edgewise Therapeutics
EWTX
$4.76B
$4.01M 0.74%
98,800
+33,300
+51% +$1.15M
BIIB icon
31
Biogen
BIIB
$31.4B
$3.98M 0.74%
18,437
– –
XENE icon
32
Xenon Pharmaceuticals
XENE
$5.77B
$3.92M 0.72%
65,000
– –
BLTE
33
Belite Bio
BLTE
$7.77B
$3.85M 0.71%
24,989
– –
MLYS icon
34
Mineralys Therapeutics
MLYS
$2.75B
$3.72M 0.69%
137,800
– –
PROK icon
35
ProKidney
PROK
$416M
$3.69M 0.68%
1,806,939
– –
ELVN icon
36
Enliven Therapeutics
ELVN
$4.35B
$3.66M 0.68%
72,100
+51,200
+245% +$2.17M
ORKA
37
Oruka Therapeutics
ORKA
$6.24B
$3.18M 0.59%
+33,400
New +$2.23M
PTGX icon
38
Protagonist Therapeutics
PTGX
$9.44B
$2.81M 0.52%
22,951
+20
+0.1% +$2.09K
UTHR icon
39
United Therapeutics
UTHR
$21.4B
$2.71M 0.5%
5,000
– –
DRUG
40
Bright Minds Biosciences
DRUG
$657M
$2.7M 0.5%
38,407
– –
KNSA icon
41
Kiniksa Pharmaceuticals
KNSA
$6.01B
$1.87M 0.34%
29,200
– –
CMPX icon
42
Compass Therapeutics
CMPX
$398M
$839K 0.15%
+383,200
New +$1.13M
PRAX icon
43
Praxis Precision Medicines
PRAX
$9.84B
$837K 0.15%
2,500
– –
KOD icon
44
Kodiak Sciences
KOD
$2.2B
$663K 0.12%
17,019
– –
TENX icon
45
Tenax Therapeutics
TENX
$74.1M
$612K 0.11%
42,080
– –
NUVL
46
DELISTED
Nuvalent
NUVL
$605K 0.11%
4,900
– –
PEPG icon
47
PepGen
PEPG
$222M
$370K 0.07%
205,324
– –
SYRE icon
48
Spyre Therapeutics
SYRE
$8.01B
$355K 0.07%
+4,000
New +$292K
ABBV icon
49
AbbVie
ABBV
$440B
– –
-14,500
Closed -$3.15M
APGE
50
DELISTED
Apogee Therapeutics
APGE
– –
-5,886
Closed -$495K
1
2
3

Similar funds

CA
CV Advisors Aventura, Florida $542M AUM 24.89% 1-Year Est. Return
WCM
Westerly Capital Management San Francisco, California $542M AUM 48.48% 1-Year Est. Return
LI
Louisbourg Investments Dieppe, New Brunswick, Canada $542M AUM 21.44% 1-Year Est. Return
CWWM
Clear Wave Wealth Management Red Bank, New Jersey $541M AUM
FVCM
F&V Capital Management Boca Raton, Florida $542M AUM 46.38% 1-Year Est. Return
LI
Lafayette Investments Ashton, Maryland $542M AUM 22.5% 1-Year Est. Return
CCT
Chemung Canal Trust Elmira, New York $541M AUM 32.42% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

Artia Global Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Artia Global Partners held 57 positions worth $542M, up 8.5% from $499M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Artia Global Partners deployed $30.9M of net new capital in Q2 2026, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Alkermes: 448,964 shares worth $23.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 89% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Abivax, an estimated $9.54M trimmed.

  • Artia Global Partners's largest Q2 2026 buy was Alkermes: 448,964 shares worth $23.5M.
  • Artia Global Partners added most to BrightSpring Health Services in Q2 2026, an estimated $25.7M increase.
  • Artia Global Partners's biggest Q2 2026 reduction was Abivax, cutting an estimated $9.54M.
  • Artia Global Partners fully exited Eli Lilly in Q2 2026, selling an estimated $35.2M.
  • Artia Global Partners's ten largest holdings make up 65% of its $542M portfolio in Q2 2026.
  • Artia Global Partners opened 7 new positions and closed 9 in Q2 2026.
  • Artia Global Partners's portfolio value rose 8.5% quarter-over-quarter to $542M.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.